Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd alone or in combinations for HER2-expressing gastric, GEJ, and esophageal cancer
NL-OMON59891Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in gastric cancer (GC), esophagogastric junction cancer and esophageal cancer (7 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in Part 1, Recommended Phase 2 dose in Part 1 and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal cancer
Beyond the preview
Go deeper on NL-OMON59891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59891.